Whatever the reason for the EOY drop, catalysts ab

Whatever the reason for the EOY drop, catalysts abound in the coming 6 months including topline results for MAT 9001's head-to-head trial vs. Vascepa, and DSMC authorization to dose the next cohort of patients in the NIH funded MAT 2203 trial for the LNC version of amphotericin b.

The muscular dystrophy foundation funded study of MAT 2501--the LNC version of amikacin--and results from numerous collaborations with BP, including Gilead, Sanofi, and Regeneron, also loom on the horizon.

Note that Matinas' market cap is only a fraction of Amarin, whose primary product, Vascepa, I expect will soon be shown to be far less effective than MAT 9001 in reducing triglycerides.

Also note that Matinas' market cap is only a fraction of that of Insmed whose primary product is an inhalable version of amphotericin b I expect will soon be shown to be more toxic, and less effective, than MAT 2202, which is an oral LNC version of this drug.

Led by a strong management team, I fully expect Matinas to trade at many multiples of its current SP in 2021.

LM

The Lawmanstyle="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]